Table 1.

Summarized data of the included patients at diagnosis and at time of sRARP

Patient no.	Status at diagnosis				Status at sRARP
	PSA (ng/mL)	Clinical stage	No. of positive cores	Gleason score	PSA (ng/mL)	Pathological stage	No. of positive cores	Estimated extension (%)	Gleason score	Surgical margins	Androgen deprivation
1	8.8	cT3b	12/12	3 + 4	2.2	pT3a	5/6	40	4 + 3	Negative	Bicalutamide
2	52.0	cT3b	10/11	4 + 5	3.8	pT3b	1/6	30	4 + 5	Positive	Degarelix
3	22.0	cT3b	7/10	4 + 5	2.8	pT2a	4/12	10	4 + 5	Negative	Triptorelin
4	61.0	cT3a	12/12	4 + 5	4.0	pT3b	12/12	75	5 + 4	Positive	Triptorelin
5	7.8	cT3a	7/7	4 + 4	3.9	pT2c	12/12	40	4 + 3	Positive	Triptorelin